ADAPTIVE TCR CORPORATION

Basic Information

1551 Eastlake Avenue East
Suite 200
SEATTLE, WA, 98102-

Company Profile

n/a

Additional Details

Field Value
DUNS: 832591544
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

    Amount: $244,699.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune di ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling

    Amount: $165,191.00

    DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $2,528,467.00

    DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants ...

    SBIR Phase II 2013 Department of Health and Human Services
  4. SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    Amount: $266,199.00

    Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and glob ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. Correlating TCR diversity to immune reconstitution after cord blood transplant

    Amount: $148,999.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direc ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Development of T-cell receptor repertoire profiling as a diagnostic for T1D

    Amount: $632,685.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is the identification of a molecular signature in the T-cell receptor repertoire of early-stage Type 1 Diabetes (T1D) patients th ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government